Dimension Therapeutics, Inc. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 14 rows, 14 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2015-10-27: Reporting owner ISALY SAMUEL D | ORBIMED ADVISORS LLC | OrbiMed Capital GP V LLC; Form 4; Security Series A Preferred Stock; Transaction C Conversion of derivative security.
- 2015-10-27: Reporting owner ISALY SAMUEL D | ORBIMED ADVISORS LLC | OrbiMed Capital GP V LLC; Form 4; Security Series B Preferred Stock; Transaction C Conversion of derivative security.
- 2015-10-27: Reporting owner Gupta Rishi; Form 4; Security Series A Preferred Stock; Transaction C Conversion of derivative security.
- 2015-10-27: Reporting owner Gupta Rishi; Form 4; Security Series B Preferred Stock; Transaction C Conversion of derivative security.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2015-10-27 | ISALY SAMUEL D | ORBIMED ADVISORS LLC | OrbiMed Capital GP V LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −9,500,000 0 owned after | no price filed | 2015-10-29 | |
| 2015-10-27 | ISALY SAMUEL D | ORBIMED ADVISORS LLC | OrbiMed Capital GP V LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series B Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −5,692,874 0 owned after | no price filed | 2015-10-29 | |
| 2015-10-27 | Gupta Rishi Director, 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −9,500,000 0 owned after | no price filed | 2015-10-29 | |
| 2015-10-27 | Gupta Rishi Director, 10% Owner | 4 | Series B Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −5,692,874 0 owned after | no price filed | 2015-10-29 | |
| 2015-10-27 | Dybbs Michael Director | 4 | Series B Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −3,208,711 0 owned after | no price filed | 2015-10-29 | |
| 2015-10-27 | FMR LLC | 4 | Series A Preferred Stock Derivative · Indirect · Beacon Bioventures Fund III Limited Partnership | C Conversion of derivative security | +15,000,000 0 owned after | no price filed | 2015-10-29 | |
| 2015-10-27 | FMR LLC | 4 | Series B Preferred Stock Derivative · Indirect · Beacon Bioventures Fund III Limited Partnership | C Conversion of derivative security | +4,761,313 0 owned after | no price filed | 2015-10-29 | |
| 2015-10-21 holding as of filing | ORBIMED ADVISORS LLC Director, 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2015-10-21 | ||
| 2015-10-21 holding as of filing | ORBIMED ADVISORS LLC Director, 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2015-10-21 | ||
| 2015-10-21 holding as of filing | Dybbs Michael Director | 3 | Series B Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2015-10-21 | ||
| 2015-10-21 holding as of filing | Gupta Rishi Director, 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2015-10-21 | ||
| 2015-10-21 holding as of filing | Gupta Rishi Director, 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2015-10-21 | ||
| 2015-10-21 holding as of filing | FMR LLC | 3 | Series A Preferred Stock Derivative · Indirect · Beacon Bioventures Fund III Limited Partnership | Holding | no price filed | 2015-10-21 | ||
| 2015-10-21 holding as of filing | FMR LLC | 3 | Series B Preferred Stock Derivative · Indirect · Beacon Bioventures Fund III Limited Partnership | Holding | no price filed | 2015-10-21 |